Beam Therapeutics Inc BEAM:NASDAQ

Last Price$68.02NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$66.00 (1)
Ask (Size)$69.80 (10)
Day Low / HighN/A - N/A
Volume1.1 M
 

Read more news Recent News

Update: Beam Shares Jump After US FDA Approves Investigational New Drug Application for Sickle Cell Therapy
1:28PM ET 11/08/2021 MT Newswires

Beam Therapeutics (BEAM) shares were up more than 9% Monday afternoon after the company said that the US Food and Drug Administration cleared its...

Beam Therapeutics Reports Narrower Q3 Loss
6:55AM ET 11/08/2021 MT Newswires

Beam Therapeutics (BEAM) on Monday reported a net loss of $0.42 per share in Q3, narrower than last year's net loss of $0.69 per share. Analysts surveyed...

Sana Biotechnology Signs Deal For Nonexclusive Commercial Rights to Beam Therapeutics' Cas12b Gene Editing Technology
10:20AM ET 10/19/2021 MT Newswires

Sana Biotechnology (SANA) struck a deal to gain nonexclusive commercial rights to Beam Therapeutics' (BEAM) CRISPR Cas12b nuclease system for certain ex...

SVB Leerink Starts Beam Therapeutics at Outperform With $117 Price Target
7:54AM ET 10/19/2021 MT Newswires

Beam Therapeutics (BEAM) has an average investment rating of outperform and price targets ranging from $85 to $150, according to analysts polled by Capital...

Company Profile

Business Description
Number of EmployeesN/A

Company Highlights

Price Open$72.55
Previous Close$72.56
52 Week Range$56.29 - 138.52
Market Capitalization$4.6 B
Shares Outstanding68.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/21/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$6.24
Beta vs. S&P 500N/A
RevenueN/A
Net Profit Margin-51,395.01%
Return on Equity-77.55%

Analyst Ratings as of 11/08/2021

Buy
8
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset